Cell Therapies, Small Molecules
Total Trials
2
As Lead Sponsor
0
As Collaborator
Total Enrollment
125
NCT05105035
Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Treatment of Melioidosis in Hospitalized Patients
Phase: Phase 2
Role: Collaborator
Start: Jun 14, 2022
Completion: Oct 10, 2023
NCT06023368
Reducing Port Access Pain and Clinic Wait Time: An Evaluation of EMLA Cream Versus nüm™ Vapocoolant Spray
Phase: Phase 4
Start: Dec 23, 2023
Completion: Jun 20, 2024
Loading map...